BCR and leukemia: In accordance with data from extensive studies on the dose-dependent effects and time kinetics of IM [38], [39], [40] we applied lower IM doses (range: 0.5 μM to 2.5 μM) for leukemia-derived BCR-ABL-positive cells (K562 and LAMA-84) than for BCR-ABL-negative cells (range: 2.5 μM to 10 μM).